Corcept CDO sells 20K shares after option exercise
Corcept Therapeutics’ Chief Development Officer William Guyer reported an exercise-and-sell transaction in company stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Corcept Therapeutics’ Chief Development Officer William Guyer reported an exercise-and-sell transaction in company stock. He exercised options to acquire 20,000 shares of common stock at a price of $21.65 per share, then sold 20,000 shares at a weighted average price of $70.60 per share in an open-market transaction.
The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 27, 2024. Following these transactions, he directly holds 3,985 shares of common stock and stock options for 150,000 shares that are fully exercisable, along with additional unvested restricted stock awards scheduled to vest one year after their respective grant dates.
Insider Trade Summary 10b5-1
Exercise and Sale: 20,000 shares ($979K approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
Guyer William
Role
Chief Development Officer
Sold
20,000 shs ($1.41M)
Approx. gross sale proceeds
$1.41M
Approx. exercise cost
$433K
Approx. pre-tax spread
$979K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) | 20,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 20,000 | $21.65 | $433K |
| Sale | Common Stock | 20,000 | $70.60 | $1.41M |
Holdings After Transaction:
Stock Option (right to buy) — 150,000 contracts (Direct);
Common Stock — 3,985 shares (Direct)
Footnotes (4)
- F1. Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 877 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
- F2. This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction.
- F3. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $70.44 to $70.86 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- F4. Fully exercisable.
Key Figures
Shares sold: 20,000 shares
Sale price: $70.60 per share
Options exercised: 20,000 shares
+5 more
8 metrics
Shares sold
20,000 shares
Open-market sale of common stock on June 2, 2026
Sale price
$70.60 per share
Weighted average sale price, range $70.44–$70.86
Options exercised
20,000 shares
Common stock acquired via option exercise on June 2, 2026
Option exercise price
$21.65 per share
Stock option (right to buy) conversion price
Common shares held
3,985 shares
Direct common stock ownership after transactions
Options outstanding
150,000 options
Stock options remaining after 20,000-share exercise, fully exercisable
Unvested RSA December 2025
224 shares
Restricted stock award granted December 1, 2025, vests after one year
Unvested RSA March 2026
498 shares
Restricted stock award granted March 2, 2026, vests after one year
Key Terms
Rule 10b5-1 plan, restricted stock awards, Stock Option (right to buy), weighted average sale price, +1 more
5 terms
Rule 10b5-1 plan regulatory
"This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024"
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
restricted stock awards financial
"Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person"
Restricted stock awards are company shares given to employees or executives that cannot be sold or transferred until certain conditions — like staying with the company for a set time or meeting performance targets — are met, like a gift that is locked in a safe until rules are satisfied. Investors care because these awards tie management’s pay to company performance, can increase the number of shares outstanding when they become tradable (dilution), and may signal expected future selling pressure or commitment to long-term growth.
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
weighted average sale price financial
"Represents the weighted average sale price for the entire number of shares sold"
fully exercisable financial
"Fully exercisable."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Corcept (CORT) executive William Guyer do in this Form 4?
William Guyer, Corcept’s Chief Development Officer, exercised options for 20,000 shares at $21.65 and sold 20,000 shares at a weighted average price of $70.60. These transactions were routine insider movements reported for regulatory transparency.
What stock options did William Guyer exercise in Corcept (CORT)?
He exercised stock options covering 20,000 shares of Corcept common stock at an exercise price of $21.65 per share. After this exercise, he still holds options for 150,000 shares that are fully exercisable and expire on September 1, 2031, according to the filing.
What unvested restricted stock awards does William Guyer hold at Corcept (CORT)?
He holds restricted stock awards covering 224 shares granted December 1, 2025, 498 shares granted March 2, 2026, and 877 shares granted June 1, 2026. All underlying shares vest on each award’s one-year anniversary, subject to stated service requirements.
AI-generated analysis. How Rhea-AI works. Not financial advice.
